Evolution of vaccination rates after the implementation of a free systematic pneumococcal vaccination in Catalonian older adults: 4-years follow-up

Vila-Córcoles, Angel; Ochoa-Gondar, Olga; Ester, Francisco; Sarrá, Nuria; Xabier Ansa; Saún, Neus
January 2006
BMC Public Health;2006, Vol. 6 Issue 1, p231
Academic Journal
Background: The systematic vaccination with 23-valent polysaccharide pneumococcal vaccine (PPV) was introduced as a strategic objective of health for all the people over 65 in Catalonia in 1999. We analysed the evolution of the pneumococcal vaccination rates from 2000 to 2003. Methods: We conducted a retrospective population-based study including all the individuals 65 years or older assigned to 8 Primary Care Centres (PCCs) in Tarragona (Catalonia, Spain), who figured in the administrative population databases on 31 December 2003 (n = 10,410 persons). We assessed whether every person had received PPV during the last four years (2000 to 2003) or whether they had received it before January 2000. Data sources were the computerised clinical records of the 8 participating PCCs, which included adult vaccination registries and diagnoses coded of International Classification of Diseases 9th Review Results: The overall vaccination uptake increased to 38.6% at the end of 2000. Global accumulated coverages increased more slowly the following years: 44.4% in 2001, 50.9% in 2002, and 53.1% at the end of 2003. Vaccine uptake varied significantly according to age (46.7% in people 65-74 years-old, 60.9% in people 75 years or more; p < 0.001) and number of diseases or risk factors (DRFs) for pneumonia (47.1% vaccinated in people without DRFs, 56.8% in patients with one DRF, and 62.2% in patients with two or more DRFs; p < 0.001). The highest coverages were observed among those patients with: diabetes (65.9%), active neoplasia (64.8%), history of stroke (63.7%), and chronic lung disease (63.5%). The lowest uptake was observed among smokers (48.7%). Discussion: The pneumococcal vaccination coverage increased quickly after the introduction of the recommendation for free vaccination in all the elderly people (with and without risk factors), but two years after the improvement the coverage became stable and increased slowly.


Related Articles

  • Curbing a bacterial menace. Foster, Stephan L. // Pharmacy Today;Aug2010 Supplement, p5 

    In this article, the author offers his views on the role played by pharmacists in addressing the pneumococcal immunization gap and reducing the impact of this virulent bacterial threat in the U.S. He believes that pharmacists are in the best position to help increase pneumococcal vaccine uptake...

  • Vaccination delivery by chain pharmacies in California: Results of a 2007 survey. Pilisuk, Tammy; Goad, Jeffery; Backer, Howard // Journal of the American Pharmacists Association: JAPhA;Mar/Apr2010, Vol. 50 Issue 2, p134 

    Objective: To better understand the practice standards and scope of pharmacist-administered vaccination services at chain pharmacies in California. Design: Cross sectional. Setting: California in 2006-2007. Participants: Eight state-level immunization coordinator corporate liaisons to chain...

  • Revaccinate against pneumococcal disease? Pinkowish, Mary Desmond // Patient Care;11/30/1994, Vol. 28 Issue 19, p90 

    Reports that older adults who received the 23-valent pneumococcal polysaccharide vaccine six or more years ago may need revaccination. Antibody determinations; Antibody levels against one third of the pneumococcal serotypes.

  • Pneumococcal vaccine encore? M.O.R. // Cortlandt Forum;2/25/96, Vol. 9 Issue 2, p112 

    Responds to queries on administering pneumococcal polysaccharide vaccine. Age of vaccine administration; Recommendations for revaccination.

  • Conjugate Pneumococcal Vaccines: Need and Choice in India. Malik, Akash // Indian Journal of Community Medicine;Oct-Dec2013, Vol. 38 Issue 4, p189 

    The authors reflect on the capability of pneumococcal vaccines as a public health tool to reduce the burden of pneumococcal diseases in developing countries including India. They discuss topics such as the common risk factors leading to the development of pneumonia, the interventions targeted on...

  • Erratum.  // Drugs;2012, Vol. 72 Issue 16, p2176 

    A correction to the article "Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed): In Older Adults" that was published in the June 2012 issue is presented.

  • New vaccines for the prevention of pneumococcal infections. Kayhty, Helena; Eskola, Juhani // Emerging Infectious Diseases;Oct-Dec96, Vol. 2 Issue 4, p289 

    Provides information on the capsular polysaccharide vaccine, a vaccine used in the prevention of pneumococcal infections. Properties of the pathogenic bacteria Streptococcus pneumoniae (Pnc); Characteristics of pneumococcal protein vaccine candidates; Results from preclinical and clinical...

  • Infant Vaccine Helps Seniors, Too.  // AARC Times;Oct2013, Vol. 37 Issue 10, p79 

    The article discusses a Vanderbilt University research report published in the July 11, 2013 issue of "The New England Journal of Medicine" regarding the benefits of the infant vaccine against pneumococcal bacteria on older adults.

  • Clarifications about pneumococcal vaccines. Morgenstern, Diana; Garcia-Curiel, Carmen S. // American Journal of Health-System Pharmacy;2/1/2010, Vol. 67 Issue 3, p183 

    A correction to an article on pneumococcal vaccine that was published in June 15, 2009 issue is presented.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics